Financial Review: CASI Pharmaceuticals (CASI) & Its Rivals

CASI Pharmaceuticals (NASDAQ:CASI) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare CASI Pharmaceuticals to similar businesses based on the strength of its institutional ownership, dividends, risk, analyst recommendations, valuation, earnings and profitability.

Volatility and Risk

CASI Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, CASI Pharmaceuticals’ rivals have a beta of -4.04, indicating that their average stock price is 504% less volatile than the S&P 500.

Insider & Institutional Ownership

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for CASI Pharmaceuticals and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1	0	0	0	1.00
CASI Pharmaceuticals Competitors	7792	13886	25777	1037	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 25.65%. Given CASI Pharmaceuticals’ rivals stronger consensus rating and higher possible upside, analysts clearly believe CASI Pharmaceuticals has less favorable growth aspects than its rivals.

Valuation and Earnings

This table compares CASI Pharmaceuticals and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85 million	-$39.26 million	-0.07
CASI Pharmaceuticals Competitors	$3.54 billion	$3.17 billion	554.50

CASI Pharmaceuticals’ rivals have higher revenue and earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares CASI Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
CASI Pharmaceuticals Competitors	-2,372.59%	-220.82%	-15.99%

Summary

CASI Pharmaceuticals rivals beat CASI Pharmaceuticals on 9 of the 13 factors compared.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.